Femasys is trading at $1.65, up +5.71%, with biotech-sector strength providing context, not a confirmed catalyst.
- XBI is up 2.20% during regular trading, in the same direction.
- No clear Femasys-specific announcement explaining the October 15 move was found. The latest company news was an October 14 update that FemBloc’s pivotal trial expanded to twelve enrolling sites; it preceded today’s trading and does not establish the cause of the rise.